论文部分内容阅读
目的分析探讨布地奈德雾化吸入联合孟鲁司特治疗小儿哮喘的临床效果。方法选取2010年8月至2013年8月患有支气管哮喘的98例小儿患者作为研究对象,将其随机分成对照组和治疗组,每组49例;所有患者均给予镇咳、吸氧、化痰以及抗感染等基础治疗;对照组在此基础上加布地奈德雾化吸入治疗,治疗组则给予布地奈德雾化吸入的同时加孟鲁司特钠咀嚼片进行治疗;治疗结束后对两组患儿在治疗过程中出现的喘息、气促、肺部鸣音等改善情况进行观察分析并对比。结果治疗组治疗后总有效率为97.96%,对照组为79.59%,治疗组明显高于对照组,差异有统计学意义(P<0.05)。结论采取布地奈德雾化吸入联合孟鲁司特口服治疗小儿哮喘疗效非常显著,同时降低了糖皮质激素的用量,有效降低了复发率,值得临床推广使用。
Objective To investigate the clinical effect of inhaled budesonide combined with montelukast on children asthma. Methods A total of 98 children with bronchial asthma from August 2010 to August 2013 were selected as study subjects and randomly divided into control group and treatment group with 49 cases in each group. All patients were given antitussive, Sputum and anti-infective and other basic treatment; the control group on this basis, add budesonide atomization inhalation treatment, the treatment group was given budesonide inhalation at the same time plus montelukast sodium chewable tablets for treatment; after treatment Two groups of children in the course of treatment of wheezing, shortness of breath, lung sounds and other improvements observed and compared. Results After treatment, the total effective rate was 97.96% in the treatment group and 79.59% in the control group, which was significantly higher in the treatment group than in the control group (P <0.05). Conclusion The use of budesonide inhalation combined with montelukast oral treatment of pediatric asthma is very significant effect, while reducing the amount of glucocorticoid, effectively reducing the recurrence rate, worthy of clinical promotion and use.